S&P 500   3,971.52 (-0.15%)
DOW   32,489.94 (+0.18%)
QQQ   306.43 (-0.75%)
AAPL   156.94 (-0.85%)
MSFT   273.78 (-0.94%)
META   200.14 (-1.33%)
GOOGL   100.61 (-1.81%)
AMZN   97.72 (-0.33%)
TSLA   188.98 (-1.48%)
NVDA   262.74 (-0.97%)
NIO   9.16 (+2.58%)
BABA   96.02 (+11.50%)
AMD   93.83 (-2.88%)
T   18.92 (+0.26%)
F   11.58 (+0.52%)
MU   58.30 (-2.49%)
CGC   1.86 (-1.24%)
GE   92.96 (-0.38%)
DIS   95.55 (-0.07%)
AMC   4.64 (+1.98%)
PFE   40.19 (-0.07%)
PYPL   72.71 (-0.80%)
NFLX   328.32 (+0.20%)
S&P 500   3,971.52 (-0.15%)
DOW   32,489.94 (+0.18%)
QQQ   306.43 (-0.75%)
AAPL   156.94 (-0.85%)
MSFT   273.78 (-0.94%)
META   200.14 (-1.33%)
GOOGL   100.61 (-1.81%)
AMZN   97.72 (-0.33%)
TSLA   188.98 (-1.48%)
NVDA   262.74 (-0.97%)
NIO   9.16 (+2.58%)
BABA   96.02 (+11.50%)
AMD   93.83 (-2.88%)
T   18.92 (+0.26%)
F   11.58 (+0.52%)
MU   58.30 (-2.49%)
CGC   1.86 (-1.24%)
GE   92.96 (-0.38%)
DIS   95.55 (-0.07%)
AMC   4.64 (+1.98%)
PFE   40.19 (-0.07%)
PYPL   72.71 (-0.80%)
NFLX   328.32 (+0.20%)
S&P 500   3,971.52 (-0.15%)
DOW   32,489.94 (+0.18%)
QQQ   306.43 (-0.75%)
AAPL   156.94 (-0.85%)
MSFT   273.78 (-0.94%)
META   200.14 (-1.33%)
GOOGL   100.61 (-1.81%)
AMZN   97.72 (-0.33%)
TSLA   188.98 (-1.48%)
NVDA   262.74 (-0.97%)
NIO   9.16 (+2.58%)
BABA   96.02 (+11.50%)
AMD   93.83 (-2.88%)
T   18.92 (+0.26%)
F   11.58 (+0.52%)
MU   58.30 (-2.49%)
CGC   1.86 (-1.24%)
GE   92.96 (-0.38%)
DIS   95.55 (-0.07%)
AMC   4.64 (+1.98%)
PFE   40.19 (-0.07%)
PYPL   72.71 (-0.80%)
NFLX   328.32 (+0.20%)
S&P 500   3,971.52 (-0.15%)
DOW   32,489.94 (+0.18%)
QQQ   306.43 (-0.75%)
AAPL   156.94 (-0.85%)
MSFT   273.78 (-0.94%)
META   200.14 (-1.33%)
GOOGL   100.61 (-1.81%)
AMZN   97.72 (-0.33%)
TSLA   188.98 (-1.48%)
NVDA   262.74 (-0.97%)
NIO   9.16 (+2.58%)
BABA   96.02 (+11.50%)
AMD   93.83 (-2.88%)
T   18.92 (+0.26%)
F   11.58 (+0.52%)
MU   58.30 (-2.49%)
CGC   1.86 (-1.24%)
GE   92.96 (-0.38%)
DIS   95.55 (-0.07%)
AMC   4.64 (+1.98%)
PFE   40.19 (-0.07%)
PYPL   72.71 (-0.80%)
NFLX   328.32 (+0.20%)
LON:SN

Smith & Nephew - SN Share Forecast, Price & News

GBX 1,140
+7.00 (+0.62%)
(As of 03/27/2023 12:00 AM ET)
Add
Compare
Today's Range
1,136
▼
1,148
50-Day Range
1,114.50
▼
1,223
52-Week Range
959.20
▼
1,338.50
Volume
1.52 million shs
Average Volume
343,671 shs
Market Capitalization
£9.96 billion
P/E Ratio
5,700.00
Dividend Yield
2.81%
Price Target
GBX 1,405.50

Smith & Nephew MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
23.3% Upside
GBX 1,405.50 Price Target
Short Interest
N/A
Dividend Strength
Weak
Based on Four Factors
Sustainability
-1.95
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.56 out of 5 stars

See Top Rated MarketRank™ Stocks Here

SN stock logo

About Smith & Nephew (LON:SN) Stock

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

Receive SN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Smith & Nephew and its competitors with MarketBeat's FREE daily newsletter.

SN Stock News Headlines

March 7, 2023 | finanznachrichten.de
Smith & Nephew plc: Smith+Nephew unveils 'Precision in Motion' for its Orthopaedics Arthroplasty portfolio at AAOS 2023 Annual Meeting
March 7, 2023 | finance.yahoo.com
Smith+Nephew unveils 'Precision in Motion' for its Orthopaedics Arthroplasty portfolio at AAOS 2023 Annual Meeting
March 28, 2023 | Press Research (Ad)
Lithium Could Be 2023's Next Big Surprise
Lithium is the hottest commodity for our green future
March 6, 2023 | finance.yahoo.com
Smith+Nephew's VISIONAIRE™ Patient-Specific Instrumentation shown to improve outcome measures for total knee arthroplasty compared with conventional instrumentation
March 1, 2023 | msn.com
Should investors buy Smith & Nephew shares today?
February 28, 2023 | finance.yahoo.com
Smith & Nephew plc (NYSE:SNN) Q4 2022 Earnings Call Transcript
February 25, 2023 | msn.com
Investors should buy these FTSE stalwarts in March!
February 23, 2023 | uk.finance.yahoo.com
Smith+Nephew shares: huge growth stock potential?
March 28, 2023 | Press Research (Ad)
Lithium Could Be 2023's Next Big Surprise
Lithium is the hottest commodity for our green future
February 23, 2023 | finance.yahoo.com
Smith & Nephew Full Year 2022 Earnings: EPS Misses Expectations
February 21, 2023 | msn.com
Smith & Nephew profits shrink as medical products maker sees higher inventory costs - but shares jump on positive outlook
February 17, 2023 | msn.com
BUSINESS LIVE: Retail sales rose 0.5% last month; NatWest profits jump by a third to £5.1bn; Rupert Soames to join Smith & Nephew
February 17, 2023 | msn.com
Smith+Nephew names ex-Serco Group CEO Rupert Soames as chair designate
February 11, 2023 | msn.com
2 FTSE 100 shares with new catalysts for growth
January 12, 2023 | finance.yahoo.com
Calculating The Fair Value Of Smith & Nephew plc (LON:SN.)
January 8, 2023 | benzinga.com
Smith & Nephew Stock (NYSE:SNN), Quotes and News Summary
January 4, 2023 | msn.com
Ft. Smith man charged with manslaughter following nephew's death in custody
December 8, 2022 | finance.yahoo.com
With 88% ownership of the shares, Smith & Nephew plc (LON:SN.) is heavily dominated by institutional owners
November 29, 2022 | msn.com
Will Smith Revealed His 9-Year-Old Nephew’s Eye-Opening Reaction After Oscars Slap
November 24, 2022 | finance.yahoo.com
Great news for Smith & Nephew plc (LON:SN.): Insiders acquired stock in large numbers last year
November 1, 2022 | finance.yahoo.com
Smith+Nephew expands procedural innovation with introduction of JOURNEY™ II ROX™ Total Knee Solution
October 18, 2022 | finance.yahoo.com
Investors in Smith & Nephew (LON:SN.) have unfortunately lost 36% over the last three years
October 12, 2022 | msn.com
Smith & Nephew site could be developed sooner as part of government's Investment Zone plans
September 26, 2022 | finance.yahoo.com
GSK Taps Burberry Executive As CFO
September 26, 2022 | finance.yahoo.com
Smith+Nephew first to market with revision knee indication on robotics platform
September 21, 2022 | finance.yahoo.com
Smith+Nephew Academy expands global access to professional medical education through virtual reality and other advanced simulation technologies
September 19, 2022 | finance.yahoo.com
Smith+Nephew launches OR3O™ Dual Mobility System in Japan for use in primary and revision hip arthroplasty
See More Headlines
Receive SN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Smith & Nephew and its competitors with MarketBeat's FREE daily newsletter.

SN Company Calendar

Today
3/28/2023
Ex-Dividend for 5/17 Dividend
3/30/2023
Dividend Payable
5/17/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
LON
Industry
Medical Appliances & Equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
LON:SN
CUSIP
N/A
CIK
N/A
Web
www.smith-nephew.com
Phone
+44-20-74017646
Fax
N/A
Employees
18,369
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
GBX 1,405.50
High Stock Price Forecast
GBX 1,500
Low Stock Price Forecast
GBX 1,243
Forecasted Upside/Downside
+23.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

EPS (Most Recent Fiscal Year)
GBX 0.20
Trailing P/E Ratio
5,700.00
Forward P/E Ratio
16.52
P/E Growth
1.27
Net Income
£223 million
Net Margins
4.28%
Pretax Margin
N/A
Return on Equity
4.12%
Return on Assets
3.98%

Debt

Debt-to-Equity Ratio
54.61
Current Ratio
2.25
Quick Ratio
0.84

Sales & Book Value

Annual Sales
£5.22 billion
Price / Sales
1.91
Cash Flow
GBX 61.01 per share
Price / Cash Flow
18.68
Book Value
GBX 604 per share
Price / Book
1.89

Miscellaneous

Outstanding Shares
873,360,000
Free Float
N/A
Market Cap
£9.96 billion
Optionable
Optionable
Beta
0.35

Key Executives

  • Ms. Anne-Francoise Nesmes (Age 51)
    CFO & Exec. Director
    Comp: $1.71M
  • Dr. Deepak S. Nath Ph.D. (Age 50)
    CEO & Director
  • Mr. Paul Connolly (Age 55)
    Pres of Global Operations
  • Mr. Andrew Swift
    VP of Investor Relations
  • Ms. Helen Barraclough (Age 44)
    Group Gen. Counsel, Company Sec. & Director
  • Ms. Alison Parkes (Age 51)
    Chief Compliance Officer
  • Mr. Joe Metzger
    Sr. VP of Marketing Services & Communications
  • Ms. Elga Lohler (Age 55)
    Chief HR Officer
  • Mr. Philip G. Cowdy (Age 56)
    Chief Bus. Devel. & Corp. Affairs Officer
  • Mr. Bradley Cannon (Age 55)
    Pres of Orthopaedics, Sports Medicine & ENT and Americas

Key Competitors

View All Competitors

Insiders

View All Insider Transactions













SN Stock - Frequently Asked Questions

Should I buy or sell Smith & Nephew stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Smith & Nephew in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SN shares.
View SN analyst ratings or view top-rated stocks.

What is Smith & Nephew's stock price forecast for 2023?

7 analysts have issued 1 year price targets for Smith & Nephew's stock. Their SN share price forecasts range from GBX 1,243 to GBX 1,500. On average, they predict the company's stock price to reach GBX 1,405.50 in the next twelve months. This suggests a possible upside of 23.3% from the stock's current price.
View analysts price targets for SN or view top-rated stocks among Wall Street analysts.

How have SN shares performed in 2023?

Smith & Nephew's stock was trading at GBX 1,109.50 at the beginning of 2023. Since then, SN stock has increased by 2.7% and is now trading at GBX 1,140.
View the best growth stocks for 2023 here.

How often does Smith & Nephew pay dividends? What is the dividend yield for Smith & Nephew?

Smith & Nephew announced a dividend on Tuesday, February 21st. Shareholders of record on Thursday, March 30th will be paid a dividend of GBX 0.23 per share on Wednesday, May 17th. This represents a dividend yield of 1.65%. The ex-dividend date of this dividend is Thursday, March 30th. This is an increase from the stock's previous dividend of GBX 0.14. The official announcement can be viewed at this link.
Read our dividend analysis for SN.

Is Smith & Nephew a good dividend stock?

Smith & Nephew (LON:SN) pays an annual dividend of GBX 32 per share and currently has a dividend yield of 2.76%. The dividend payout ratio is 16,000.00%. Payout ratios above 75% are not desirable because they may not be sustainable.
Read our dividend analysis for SN.

What other stocks do shareholders of Smith & Nephew own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Smith & Nephew investors own include Imperial Brands (IMB), Smith & Nephew (SNN), Alexion Pharmaceuticals (ALXN), Barclays (BARC), GSK (GSK), Diageo (DGE), Standard Chartered (STAN), Unilever (ULVR), British American Tobacco (BATS) and BHP Group (BHP).

What is Smith & Nephew's stock symbol?

Smith & Nephew trades on the London Stock Exchange (LON) under the ticker symbol "SN."

How do I buy shares of Smith & Nephew?

Shares of SN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Smith & Nephew's stock price today?

One share of SN stock can currently be purchased for approximately GBX 1,140.

How much money does Smith & Nephew make?

Smith & Nephew (LON:SN) has a market capitalization of £9.96 billion and generates £5.22 billion in revenue each year. The company earns £223 million in net income (profit) each year or GBX 0.20 on an earnings per share basis.

How many employees does Smith & Nephew have?

The company employs 18,369 workers across the globe.

How can I contact Smith & Nephew?

Smith & Nephew's mailing address is 15 Adam Street, LONDON, WC2N 6LA, United Kingdom. The official website for the company is www.smith-nephew.com. The company can be reached via phone at +44-20-74017646.

This page (LON:SN) was last updated on 3/28/2023 by MarketBeat.com Staff